BioNTech SE has announced a strategic global partnership with Bristol Myers Squibb to jointly develop and commercialize their bispecific antibody candidate, BNT327, aimed at a variety of solid tumor types. The collaboration leverages the expertise and resources of both companies, with a focus on accelerating the clinical development, potential regulatory approvals, and market launches of BNT327. This partnership will involve a 50:50 profit and loss sharing agreement and aims to establish BNT327 as a new treatment standard beyond traditional checkpoint inhibitors. BioNTech and Bristol Myers Squibb will work together to conduct an extensive clinical development program for BNT327, both as a monotherapy and in combination with other treatments, with the potential to expand indications and combinations independently.